February 19, 2020
The Japanese pharmaceutical market scored the first growth in three years in 2019 by hitting 10.62 trillion yen on an NHI price basis, with MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) nabbing the top-seller title, according to data released by IQVIA. In...read more